Skip to main content
. 2022 Dec 15;55:101771. doi: 10.1016/j.eclinm.2022.101771

Fig. 2.

Fig. 2

(A) Proportion of patients achieving complete response from days 1 to 8 (every 24 h); (B) Proportion of patients experiencing no nausea from days 1 to 8 (every 24 h); (C) Subgroup analysis of complete response during the overall phase in a subset of patients with baseline blood samples (n = 274). ECOG PS, Eastern Cooperative Oncology Group performance status; substance P (pg/mL), 5-HT (ng/mL); CI, confidence interval; n, number of patients. ∗, P < 0.05, calculated with the chi-square test.